173 related articles for article (PubMed ID: 26774260)
1. Autoantibody signatures defined by serological proteome analysis in sera from patients with cholangiocarcinoma.
Mustafa MZ; Nguyen VH; Le Naour F; De Martin E; Beleoken E; Guettier C; Johanet C; Samuel D; Duclos-Vallee JC; Ballot E
J Transl Med; 2016 Jan; 14():17. PubMed ID: 26774260
[TBL] [Abstract][Full Text] [Related]
2. Detection of autoantibodies against cyclophilin A and triosephosphate isomerase in sera from breast cancer patients by proteomic analysis.
Tamesa MS; Kuramitsu Y; Fujimoto M; Maeda N; Nagashima Y; Tanaka T; Yamamoto S; Oka M; Nakamura K
Electrophoresis; 2009 Jun; 30(12):2168-81. PubMed ID: 19582718
[TBL] [Abstract][Full Text] [Related]
3. Plasma autoantibodies against heat shock protein 70, enolase 1 and ribonuclease/angiogenin inhibitor 1 as potential biomarkers for cholangiocarcinoma.
Rucksaken R; Pairojkul C; Pinlaor P; Khuntikeo N; Roytrakul S; Selmi C; Pinlaor S
PLoS One; 2014; 9(7):e103259. PubMed ID: 25058392
[TBL] [Abstract][Full Text] [Related]
4. A Promising Serum Autoantibody Marker, Anti-Heat Shock Protein 90α, for Cholangiocarcinoma.
Boonjaraspinyo S; Juasook A; Boonmars T; Aukkanimart R; Silsirivanit A; Loilome W; Sriraj P; Wu Z; Ratanasuwan P
Asian Pac J Cancer Prev; 2015; 16(14):5779-85. PubMed ID: 26320451
[TBL] [Abstract][Full Text] [Related]
5. Proteomic analysis of autoantibodies in patients with hepatocellular carcinoma.
Takashima M; Kuramitsu Y; Yokoyama Y; Iizuka N; Harada T; Fujimoto M; Sakaida I; Okita K; Oka M; Nakamura K
Proteomics; 2006 Jul; 6(13):3894-900. PubMed ID: 16767786
[TBL] [Abstract][Full Text] [Related]
6. Circulating markers of biliary malignancy: opportunities in proteomics?
Bonney GK; Craven RA; Prasad R; Melcher AF; Selby PJ; Banks RE
Lancet Oncol; 2008 Feb; 9(2):149-58. PubMed ID: 18237849
[TBL] [Abstract][Full Text] [Related]
7. [Proteome analysis of autoantibodies in sera of patients with cancer].
Ueda K
Rinsho Byori; 2005 May; 53(5):437-45. PubMed ID: 15966408
[TBL] [Abstract][Full Text] [Related]
8. [Screening hepatocellular carcinoma autoantibodies by serological proteome analysis].
Feng JT; Liu YK; Dai Z; Zhou HJ; Song HY; Qin LX; Jin H; Lu HJ; Tang ZY
Zhonghua Gan Zang Bing Za Zhi; 2005 Nov; 13(11):832-5. PubMed ID: 16313728
[TBL] [Abstract][Full Text] [Related]
9. Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients.
Cavalloni G; Peraldo-Neia C; Massa A; Bergamini C; Trentini A; De Rosa G; Daniele L; Ciccosanti F; Cervellati C; Leone F; Aglietta M
BMC Cancer; 2021 Jul; 21(1):865. PubMed ID: 34320944
[TBL] [Abstract][Full Text] [Related]
10. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma.
Fujita Y; Nakanishi T; Hiramatsu M; Mabuchi H; Miyamoto Y; Miyamoto A; Shimizu A; Tanigawa N
Clin Cancer Res; 2006 Nov; 12(21):6415-20. PubMed ID: 17085654
[TBL] [Abstract][Full Text] [Related]
11. Identification of an anti-aldolase autoantibody as a diagnostic marker for diabetic retinopathy by immunoproteomic analysis.
Ahn BY; Song ES; Cho YJ; Kwon OW; Kim JK; Lee NG
Proteomics; 2006 Feb; 6(4):1200-9. PubMed ID: 16421937
[TBL] [Abstract][Full Text] [Related]
12. Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system.
Croci S; Recktenwald CV; Lichtenfels R; Nicoletti G; Dressler SP; De Giovanni C; Astolfi A; Palladini A; Shin-ya K; Landuzzi L; Nanni P; Lollini PL; Seliger B
Proteomics; 2010 Nov; 10(21):3835-53. PubMed ID: 20957756
[TBL] [Abstract][Full Text] [Related]
13. Mass spectrometry-based proteomic analysis of formalin-fixed paraffin-embedded extrahepatic cholangiocarcinoma.
Maeda S; Morikawa T; Takadate T; Suzuki T; Minowa T; Hanagata N; Onogawa T; Motoi F; Nishimura T; Unno M
J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):683-91. PubMed ID: 25917007
[TBL] [Abstract][Full Text] [Related]
14. Identification of melanoma antigens using a Serological Proteome Approach (SERPA).
Suzuki A; Iizuka A; Komiyama M; Takikawa M; Kume A; Tai S; Ohshita C; Kurusu A; Nakamura Y; Yamamoto A; Yamazaki N; Yoshikawa S; Kiyohara Y; Akiyama Y
Cancer Genomics Proteomics; 2010; 7(1):17-23. PubMed ID: 20181627
[TBL] [Abstract][Full Text] [Related]
15. Identification of plasma membrane autoantigens in autoimmune hepatitis type 1 using a proteomics tool.
Tahiri F; Le Naour F; Huguet S; Lai-Kuen R; Samuel D; Johanet C; Saubamea B; Tricottet V; Duclos-Vallee JC; Ballot E
Hepatology; 2008 Mar; 47(3):937-48. PubMed ID: 18306218
[TBL] [Abstract][Full Text] [Related]
16. Differential LC-MS-based proteomics of surgical human cholangiocarcinoma tissues.
Kawase H; Fujii K; Miyamoto M; Kubota KC; Hirano S; Kondo S; Inagaki F
J Proteome Res; 2009 Aug; 8(8):4092-103. PubMed ID: 19569727
[TBL] [Abstract][Full Text] [Related]
17. Serum α1β-glycoprotein and afamin ratio as potential diagnostic and prognostic markers in cholangiocarcinoma.
Tolek A; Wongkham C; Proungvitaya S; Silsirivanit A; Roytrakul S; Khuntikeo N; Wongkham S
Exp Biol Med (Maywood); 2012 Oct; 237(10):1142-9. PubMed ID: 23104505
[TBL] [Abstract][Full Text] [Related]
18. Cancer immunomics: from serological proteome analysis to multiple affinity protein profiling.
Hardouin J; Lasserre JP; Sylvius L; Joubert-Caron R; Caron M
Ann N Y Acad Sci; 2007 Jun; 1107():223-30. PubMed ID: 17804550
[TBL] [Abstract][Full Text] [Related]
19. New antigenic candidates in multiple sclerosis: identification by serological proteome analysis.
Almeras L; Lefranc D; Drobecq H; de Seze J; Dubucquoi S; Vermersch P; Prin L
Proteomics; 2004 Jul; 4(7):2184-94. PubMed ID: 15221778
[TBL] [Abstract][Full Text] [Related]
20. Identification of 14‑3‑3ζ as a potential biomarker in gastric cancer by proteomics‑based analysis.
Liu XX; Ye H; Wang P; Zhang Y; Zhang JY
Mol Med Rep; 2017 Nov; 16(5):7759-7765. PubMed ID: 28944820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
